-
1 day ago | 
ophthalmologytimes.com | Ellen Koo |Martin Harp |Hattie Hayes
Author(s):,Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients. Editor's note: The below transcript has been lightly edited for clarity. Hi, my name is Dr Ellen Koo. I'm an associate professor of ophthalmology at Bascom Palmer Eye Institute. I am so happy to be here with you at ARVO 2025. We presented our work today at the poster sessions.
-
1 day ago | 
modernretina.com | Hattie Hayes |Martin Harp |Alfredo A. Sadun
During the recent Association for Research in Vision and Ophthalmology (ARVO) meeting, Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared some exciting new research with the Eye Care Network. In Salt Lake City, Utah, Prof. Sadun detailed a recent project examining Leber hereditary optic neuropathy (LHON).
-
1 day ago | 
ophthalmologytimes.com | Jason Bacharach |Sheryl Stevenson |Hattie Hayes
Perfluorohexylactane may offer a fast-acting option for dry eye symptom relief, showing measurable benefits within minutes of application, explained Jason Bacharach, MD, who presented findings on the agent’s early efficacy at the 2025 American Society of Cataract and Refractive meeting, held April 25 to 28 in Los Angeles, California.
-
2 days ago | 
optometrytimes.com | AnnMarie Hipsley |Emily Kaiser Maharjan |Sheryl Stevenson |Hattie Hayes
At the 2025 ASCRS meeting in Los Angeles, a concept was shared by AnnMarie Hipsley, DPT, PhD, for optometrists seeking to stay at the forefront of precision ocular care—the Digital Twin. More than a buzzword, a digital twin represents a virtual simulation of a real-world anatomical system, in this case, the human eye.
-
5 days ago | 
optometrytimes.com | Mark Bullimore |Martin Harp |Hattie Hayes |Emily Kaiser Maharjan
At the 2025 ARVO conference in Salt Lake City, Mark Bullimore, MCOptom, PhD, of the University of Houston College of Optometry shared a compelling critique of the current use of centile growth curves for axial length in myopia management. Speaking directly to optometrists, Bullimore emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy. Centile growth curves based on general populations are misleading in myopia management.
-
6 days ago | 
ophthalmologytimes.com | Deborah Ristvedt |Sheryl Stevenson |Hattie Hayes
Author(s):,Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians. Deb Ristvedt, DO, moderated a session titled Medications, Lasers, and Lifestyle, highlighting the rapid evolution of glaucoma treatment paradigms at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California.
-
1 week ago | 
modernretina.com | Martin Harp |Hattie Hayes |Carl J. Danzig
Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his work in diabetic macular edema (DME) during the Association for Research in Vision and Ophthalmology (ARVO) meeting. In Salt Lake City, Utah, Dr. Danzig explained a drop-based DME treatment called OCS-01 (Oculis Holding), the subject of the ongoing phase 3 DIAMOND trial.
-
1 week ago | 
modernretina.com | Martin Harp |Hattie Hayes |Jennifer Lim
Joining the Eye Care Network in Salt Lake City, Jennifer Lim, MD, FARVO, FASRS, discussed her Association for Research in Vision and Ophthalmology (ARVO) presentation on sickle cell retinopathy. "We know that sickle cell retinopathy is fraught with complications when proliferative sickle cell stages develop, such as vitreous hemorrhage or retinal detachment," she said.
-
1 week ago | 
ophthalmologytimes.com | Martin Harp |Katherine Talcott |Hattie Hayes
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study. The research she presented focused on neovascular age-related macular degeneration (AMD). "This is actually the first phase 2 study looking at a tyrosine kinase inhibitor for wet AMD," Dr. Talcott told the Eye Care Network.
-
1 week ago | 
europe.ophthalmologytimes.com | Martin Harp |Hattie Hayes |Nitish Mehta
Editors from the Eye Care Network are onsite at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah. During the conference, we spoke with Nitish Mehta, MD, an assistant professor at New York University Langone Health in New York, NY. He shared highlights from his research, which documented real-world results of aflibercept 8 mg for patients with diabetic macular oedema (DMO).
